Activating a person’s immune response against cancer is one of the most exciting advances in cancer therapy
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. Normally our immune system fails to recognise cancer cells, as they can look like normal cells in our body and are adept at becoming invisible to immune cells. By making the cancer cells visible to the immune system, new immunotherapies can potentially be used to cure cancer.
Cancer immunotherapy – involving treatments that harness the body’s own immune system to destroy tumours – is currently one of the most exciting areas of dramatic progress in cancer research. And the ICR, has already played an important role in developing immunotherapy for patients.
CRIS wants to invest further in this important field of science and together with The Institute of Cancer Research (ICR), are working together to ensure their advances in cancer research benefit patients now and in the long-term. Together we are forming a new team which will be expected to work in association with Professor Mel Greaves FRS, Professor Raj Chopra and Professor Alan Melcher. The team will be solely dedicated to immunotherapy , funded 100% by CRIS, researching in synergy within the new state-of-the-art Centre for Cancer Drug Discovery, and will share their findings and results worldwide to find answers to the most clinically-challenging problems in cancer research, such as how to combat drug resistance.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Today, the ICR leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.